Fc gamma receptors and Complement component 1q (FcγR/C1q)

Fc gamma receptors (FcγRs) and Complement component 1q (C1q) are the primary molecular interfaces through which the humoral immune system translates antibody-antigen recognition into effector cell activity. FcγRs, including the high-affinity FcγRI (CD64) and the low-affinity FcγRII (CD32) and FcγRIII (CD16), are expressed on various leukocytes and mediate processes such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and the release of inflammatory mediators (PMID: 25611383, UniProt: P08637). C1q is the initiating protein of the classical complement pathway, which, upon binding to the Fc region of clustered antibodies, triggers a proteolytic cascade resulting in the formation of the membrane attack complex and complement-dependent cytotoxicity (CDC) (PMID: 30108525, UniProt: P02745). In the context of biopharmaceutical development, these molecules are critical therapeutic targets; monoclonal antibodies are frequently engineered (e.g., glycoengineering or amino acid substitutions) to optimize their affinity for specific FcγRs or C1q to enhance tumor killing or minimize systemic toxicity (PMID: 28107532). Genetic variations in FcγR genes, particularly the FCGR3A-V158F polymorphism, serve as important biomarkers for predicting patient response to IgG1-based therapies like rituximab and trastuzumab (PMID: 11854110). Understanding the structural basis of these interactions is essential for designing next-generation biologics with improved safety and efficacy profiles in oncology and autoimmune diseases (PMID: 31110339).

Other names

Fc gamma receptorC1qIgG Fc receptorsComplement C1qCD16/CD32/CD64 and C1qFc-gamma receptors and C1q

Monoclonal antibodies bind to Fc gamma receptors on immune effector cells to trigger ADCC and phagocytosis, while simultaneously binding to C1q to initiate the classical complement cascade leading to CDC.